{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:59:08Z","timestamp":1791471548740,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of Clinical Outcome Assessments (COA) instruments in blood cancers such as myeloproliferative neoplasms (MPN) is widely documented, however little is known about Essential Thrombocythemia (ET). A targeted literature review was conducted to identify the concepts of interest to the ET population and to develop a conceptual framework. Using this framework, identification and review of COA instruments will help determine if there are existing instruments fit for purpose for use in ET studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Targeted reviews in May and October 2023 synthesized the literature on ET symptoms and impacts to derive a conceptual model and identify suitable COAs. Eligible articles consisted of ET only populations and extended to MPN samples that included ET patients. A gap analysis was conducted on selected instruments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 890 abstracts reviewed, 206 were included in the analysis. An ET conceptual model that encompassed disease-defining concepts (fatigue most common), proximal, distal, and general life impacts was created. MPN specific measures such as the Myelofibrosis Symptom Assessment Form v4.0 (MFSAF), and Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS; MPN-10), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core Questionnaire (EORTC QLQ-C30), Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue, and Brief Fatigue Inventory (BFI) were deemed the most appropriate for the gap analysis. Each had strengths and limitations related to conceptual coverage, evidence for measurement properties, and feasibility for use in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The MFSAF v4.0, PROMIS-Fatigue, and EORTC QLQ-C30 are considered appropriate for use in deriving trial endpoints in ET; however further work is needed to assess the fitness-for-purpose in the ET population as most validation studies were performed in mixed MPN or oncology samples.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01048-7","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:24:45Z","timestamp":1790871885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted literature review to understand the patient experience of essential thrombocythemia and evaluate existing clinical outcome assessment measures"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0012-3951","authenticated-orcid":false,"given":"Amy","family":"Howerter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"McQuarrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Lloyd-Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gyorkey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Hudgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"1048_CR1","doi-asserted-by":"crossref","unstructured":"Yacoub A, Lyons R, Verstovsek S et al. (2021) Disease and clinical characteristics of patients with a clinical diagnosis of essential thrombocythemia enrolled in the MOST study. Clin Lymphoma Myeloma Leuk 21(7):461\u2013469.","DOI":"10.1016\/j.clml.2021.02.011"},{"key":"1048_CR2","doi-asserted-by":"publisher","first-page":"106711","DOI":"10.1016\/j.leukres.2021.106711","volume":"110","author":"S Verstovsek","year":"2021","unstructured":"Verstovsek S, Amoloja T, Scherber R, Yu J (2021) Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice. Leuk Res 110:106711.","journal-title":"Leuk Res"},{"issue":"13","key":"1048_CR3","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1080\/10428194.2022.2113531","volume":"63","author":"E Ritchie","year":"2022","unstructured":"Ritchie E, Al-Janadi A, Kessler C et al. (2022) Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study. Leuk Lymphoma 63(13):3138\u20133153.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1048_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s11136-018-1827-2","volume":"27","author":"F Palandri","year":"2018","unstructured":"Palandri F, Benevolo G, Iurlo A et al. (2018) Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine-results from the Italian \u2018back to life\u2019 project. Qual Life Res 27(6):1545\u20131554.","journal-title":"Qual Life Res"},{"issue":"10","key":"1048_CR5","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"C Harrison","year":"2017","unstructured":"Harrison C, Koschmieder S, Foltz L et al. (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol 96(10):1653\u20131665.","journal-title":"Ann Hematol"},{"issue":"2","key":"1048_CR6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3904\/kjim.2021.475","volume":"37","author":"J Byun","year":"2022","unstructured":"Byun J, Bang S, Choi E et al. (2022) How myeloproliferative neoplasms patients\u2019 experience and expectations differ from physicians\u2019: the international MPN Landmark survey. Korean J Intern Med 37(2):444\u2013454.","journal-title":"Korean J Intern Med"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M et al. (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey. BMC Cancer 16:1\u201310.","journal-title":"BMC Cancer"},{"issue":"1","key":"1048_CR8","first-page":"e 1655","volume":"6","author":"A Bradford","year":"2023","unstructured":"Bradford A, Young K, Whitechurch A, Burbury K, Pearson EJM (2023) Disabled, invisible and dismissed-the lived experience of fatigue in people with myeloproliferative neoplasms. Cancer Rep 6(1):e 1655.","journal-title":"Cancer Rep"},{"key":"1048_CR9","unstructured":"Voice of the patient, a report on the first externally-led patient focused drug development meeting on myeloproliferative neoplasms (MPNs), November 2021. Available at: https:\/\/www.mpnresearchfoundation.org\/wp-content\/uploads\/2021\/12\/2021-12-15-MPN-Voice-of-the-Report-FINAL-w-Cover.pdf."},{"key":"1048_CR10","unstructured":"Patients Like Me website available at: https:\/\/www.patientslikeme.com\/conditions\/essential-thrombocythemia."},{"key":"1048_CR11","doi-asserted-by":"crossref","unstructured":"Lloyd-Price L, Yang M X, Gyorkey K, Howerter J, Hudgens A, S (2024) PCR167 targeted literature review to understand the patient experience of essential thrombocythemia and to evaluate existing clinical outcome assessment measures. Value Health 27(6):S327.","DOI":"10.1016\/j.jval.2024.03.2046"},{"key":"1048_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","volume":"59","author":"C Gwaltney","year":"2017","unstructured":"Gwaltney C, Paty J, Kwitkowski VE et al. (2017) Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leukemia Res 59:26\u201331.","journal-title":"Leukemia Res"},{"issue":"33","key":"1048_CR13","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL et al. (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Educ Chang Clin Oncol 30(33):4098.","journal-title":"J Educ Chang Clin Oncol"},{"issue":"5","key":"1048_CR14","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al. (1993) The European Organization for Research and treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI: J The Natl Cancer Inst 85(5):365\u2013376.","journal-title":"JNCI: J The Natl Cancer Inst"},{"issue":"10","key":"1048_CR15","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.apmr.2010.08.033","volume":"92","author":"J-S Lai","year":"2011","unstructured":"Lai J-S, Cella D, Choi S et al. (2011) How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Archives Phys Med Rehabil 92(10):S20\u2013S27.","journal-title":"Archives Phys Med Rehabil"},{"key":"1048_CR16","unstructured":"PROMIS A brief guide to the PROMIS\u00ae Fatigue instruments. 2019, Available at: https:\/\/www.healthmeasures.net\/images\/PROMIS\/manuals\/PROMIS_Fatigue_Scoring_Manual.pdf."},{"issue":"5","key":"1048_CR17","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","volume":"85","author":"TR Mendoza","year":"1999","unstructured":"Mendoza TR, Wang XS, Cleeland CS et al. (1999) The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85(5):1186\u20131196.","journal-title":"Cancer"},{"issue":"13","key":"1048_CR18","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1080\/10428194.2022.2113531","volume":"63","author":"E Ritchie","year":"2022","unstructured":"Ritchie E, Al-Janadi A, Kessler C et al. (2022) Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study. Leuk Lymphoma 63(13):3138\u20133153.","journal-title":"Leuk Lymphoma"},{"key":"1048_CR19","unstructured":"FDA (2023. Available at: April) Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory Decision-Making. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory. 2023."},{"key":"1048_CR20","first-page":"2168","volume":"130","author":"AC Dueck","year":"2017","unstructured":"Dueck AC, Gwaltney C, Chen W-H et al. (2017) Quantitative testing of the myelofibrosis symptom assessment form version 4.0, a harmonized patient-reported outcome measure for collecting key secondary endpoint data in myelofibrosis clinical trials. Blood 130:2168.","journal-title":"Blood"},{"key":"1048_CR21","doi-asserted-by":"publisher","first-page":"106711","DOI":"10.1016\/j.leukres.2021.106711","volume":"110","author":"S Verstovsek","year":"2021","unstructured":"Verstovsek S, Amoloja T, Scherber RM, Yu J (2021) Real-world patient characteristics and treatment patterns of ruxolitinib among patients with advanced essential thrombocythemia at community clinical practice. Leukemia Res 110:106711\u2013106711.","journal-title":"Leukemia Res"},{"issue":"9","key":"1048_CR22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al. (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. NEJM Evid 366(9):799\u2013807.","journal-title":"NEJM Evid"},{"issue":"5","key":"1048_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.14740\/jh914","volume":"10","author":"BT Langlais","year":"2021","unstructured":"Langlais BT, Mazza GL, Kosiorek HE, Palmer J, Mesa R, Dueck AC (2021) Validation of a modified version of the myeloproliferative neoplasm symptom Assessment Form total symptom score. J Retailing Hematol 10(5):207.","journal-title":"J Retailing Hematol"},{"issue":"10","key":"1048_CR24","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V et al. (2013) Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Educ Chang Clin Oncol 31(10):1285.","journal-title":"J Educ Chang Clin Oncol"},{"issue":"8","key":"1048_CR25","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3899\/jrheum.200990","volume":"48","author":"JL Beaumont","year":"2021","unstructured":"Beaumont JL, Davis ES, Curtis JR, Cella D, Yun H (2021) Meaningful change thresholds for patient-reported outcomes measurement information system (PROMIS) fatigue and pain interference scores in patients with rheumatoid arthritis. J Sport Hist Rheumatol 48(8):1239\u20131242.","journal-title":"J Sport Hist Rheumatol"},{"issue":"12","key":"1048_CR26","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1007\/s11136-019-02289-4","volume":"28","author":"M Yang","year":"2019","unstructured":"Yang M, Keller S, Lin JS (2019) Psychometric properties of the PROMIS\u00ae Fatigue short Form 7a among adults with myalgic encephalomyelitis\/chronic fatigue syndrome. Qual Life Res 28(12):3375\u20133384. https:\/\/doi.org\/10.1007\/s11136-019-02289-4.","journal-title":"Qual Life Res"},{"issue":"10","key":"1048_CR27","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1093\/annonc\/mdq721","volume":"22","author":"T Luckett","year":"2011","unstructured":"Luckett T, King M, Butow P et al. (2011) Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. Ann Oncol 22(10):2179\u20132190.","journal-title":"Ann Oncol"},{"key":"1048_CR28","doi-asserted-by":"publisher","first-page":"S343","DOI":"10.1016\/j.jval.2020.04.1301","volume":"23","author":"A Nixon","year":"2020","unstructured":"Nixon A, Williams A, Theodore-Oklota C (2020) PRO80 psychometric Validation of the Brief Fatigue Inventory (BFI) in adult X-linked hypophosphatemia (XLH). Value Health 23:S343.","journal-title":"Value Health"},{"issue":"8","key":"1048_CR29","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.apmr.2014.03.026","volume":"95","author":"MJ Shuman-Paretsky","year":"2014","unstructured":"Shuman-Paretsky MJ, Belser-Ehrlich J, Holtzer R (2014) Psychometric properties of the Brief Fatigue Inventory in community-dwelling older adults. Archives Phys Med Rehabil 95(8):1533\u20131539.","journal-title":"Archives Phys Med Rehabil"},{"issue":"6","key":"1048_CR30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.5014\/ajot.2010.09198","volume":"64","author":"SL Murphy","year":"2010","unstructured":"Murphy SL, Lyden AK, Smith DM, Dong Q, Koliba JF (2010) Effects of a tailored activity pacing intervention on pain and fatigue for adults with osteoarthritis. Am J Occup Ther 64(6):869\u2013876.","journal-title":"The Am J Occup Ther"},{"issue":"1","key":"1048_CR31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M et al. (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) an international internet-based survey of 1179 MPD patients. Cancer 109(1):68\u201376.","journal-title":"Cancer"},{"issue":"9","key":"1048_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","volume":"33","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Schwager S, Radia D et al. (2009) The myelofibrosis symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leukemia Res 33(9):1199\u20131203.","journal-title":"Leukemia Res"},{"key":"1048_CR33","unstructured":"US Department of Health and Human Services FaDA (2022) Center for drug Evaluation and Research, center for Biologics Evaluation and Research, and center for Devices and Radiological Health patient-focused drug development: methods to identify what is important to patients guidance for industry. Food and Drug administration staff, and other stakeholders. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients."},{"key":"1048_CR34","unstructured":"US Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (2023 April) Center for Biologics Evaluation and Research, and center for Devices and Radiological Health patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory Decision-Making. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory."}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01048-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01048-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01048-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:35:02Z","timestamp":1791470102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01048-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01048-7","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research did not require ethics approval as it is not human subjects research.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AH, LLP, JG, and SH are employees of Clinical Outcomes Solutions who was contracted by Merck & Co., Inc. to complete the study. XY and KM are employees of Merck & Co., Inc.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"183"}}